Company
Every investor coverage indicates participated in a round Tryptamine Therapeutics raised.
Companies Tryptamine Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Jason Carroll | CEO | @AuManufacturing |
| Professor David Castle | Scientific Advisory Board Member | @AuManufacturing |
Stories naming Tryptamine Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup: BrainChip's completed placement plus an LDA Capital stake sale, Arafura's committed raise, a $76m Queensland regional fund, ARENA and ACCC appointments, a Tryp advisory hire, and Steel Cement's licence approval.